X0306 4 2013-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001502917 Stamoulis Christiana C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 0 1 0 0 SVP, Corp Strategy & Bus Devlp Common Stock 2013-02-05 4 A 0 10166 0.01 A 45712 D Common Stock 797 I 401(k) Employee Stock Option (right to buy) 45.11 2013-02-05 4 A 0 45750 0.00 A 2023-02-04 Common Stock 45750 45750 D Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Omar White, Attorney-In-Fact 2013-02-07